Activity Description and Educational Objectives

In this activity, experts in prostate cancer discuss evidence-based, individualized strategies to appropriately select and sequence therapy throughout the spectrum of disease.

Upon completion of this activity, participants should be better able to:

• Discuss the latest prostate cancer clinical trials assessing hormone, cytotoxic, immunologic, bone-directed, and other novel therapies in different settings and patient populations (eg, non-metastatic CRPC, hormone-sensitive metastatic prostate cancer, metastatic CRPC)
• Appraise current data on the efficacy and safety of approved and investigational therapies and novel combinations for prostate cancer, and the clinical implications of these data
• Recognize various tumor-, patient-, and treatment-related factors and biomarkers that can help guide the treatment of patients with prostate cancer
• Establish treatment plans for patients with prostate cancer using the latest agents in appropriate sequences or combinations in accordance with up-to-date evidence and practice/expert recommendations, and based on consideration of the relevant tumor-, patient-, treatment-related factors, and patient needs/preferences

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, uro-oncologists, radiation oncologists, and other clinicians involved in the treatment of prostate cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 29, 2016 - July 28, 2017
Time to Complete: 120 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator
Robert Dreicer, MD, MS, FACP, FASCO
Section Head Medical Oncology
Deputy Director, University of Virginia Cancer Center
Associate Director for Clinical Research
Co-Director Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Robert Dreicer, MD, MS, FACP, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant for Asana BioSciences, LLC.; Astellas Pharma, Inc.; Churchill Pharmaceuticals LLC; Exelixis, Inc.; Ferring Pharmaceuticals Inc.; Genentech, Inc.; and Medivation, Inc.

Faculty
Charles J. Ryan, MD
Professor of Clinical Medicine and Urology
Thomas Perkins Distinguished Professor in Cancer Research
Program Leader, Genitourinary Medical Oncology
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Charles J. Ryan, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca; Bayer Corporation; and Ferring Pharmaceuticals Inc.
Grant/Research Support from Karyopharm Therapeutics.
Speakers Bureau participant with Astellas Pharma, Inc. and Janssen Pharmaceuticals, Inc.

Oliver Sartor, MD
Medical Director, Tulane Cancer Center
C.E. and Bernadine Laborde Professor of Cancer Research
Professor, Departments of Medicine & Urology
Department of Hem/Onc
Tulane University School of Medicine
New Orleans, Louisiana

Oliver Sartor, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer Corporation; Bellicum Pharmaceuticals, Inc.; Bristol-Myers Squibb; Celgene Corporation; Dendreon Corporation; Johnson & Johnson Services, Inc.; Medivation, Inc.; OncoGenex Pharmaceuticals Inc.; Sanofi US; and Tokai Pharmaceuticals, Inc.
Grant/Research Support from Bayer Corporation; Dendreon Corporation; Endocyte; Innocrin Pharmaceuticals Inc.; Johnson & Johnson Services, Inc.; and Sanofi US.

Medical Director
Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education

Kathryn B. Charalambous, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5977-17-T.

Providership
This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support
This activity is supported by educational grants from Ferring Pharmaceuticals Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Sanofi US, and Tokai Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.